# DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

> **NCT03688178** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Annick Desjardins, MD** · enrollment: 43 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- **DRUG:** Temozolomide
- **BIOLOGICAL:** Varlilumab
- **BIOLOGICAL:** Td
- **BIOLOGICAL:** Unpulsed DCs

## Key facts

- **NCT ID:** NCT03688178
- **Lead sponsor:** Annick Desjardins, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-26
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03688178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03688178, "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT03688178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*